e-ISSN: Pending
Failure-mode index

Search what already failed

A searchable index of real negative results, null findings, and replication failures from the published literature — so you can learn what didn't work before repeating it.

WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record (title, authors, DOI) compiled from open scholarly databases, with the abstract shown in full only where the paper is openly licensed (e.g. Creative Commons); otherwise a short excerpt is shown for reference under fair use. WASTE classifies each work by failure type; classifications are automated and approximate.

1 result in Replication Failure for "SARS-CoV-2"

Replication FailureOpen accessMedicine

Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients

Christopher C. Butler, Andrew Pinto, Victoria Harris et al. · 2026 · New England Journal of Medicine

BACKGROUND: Nirmatrelvir-ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness of nirmatrelvir-ritonavir in persons who have been vaccinated, infected naturally, or both is unclear. METHODS: In two open-label platform trials (PANORAMIC in the United Kingdom and CanTreatCOVID in Canada), we enrolled higher-risk adults (≥50 years of age or ≥18 years of age with coexisting conditions) in the community who tested positive for SARS-CoV-2 and had been unwell for 5 day

View details →DOI: 10.1056/nejmoa2502457Cited by 9